| gap-debate-20260410- | Can context-dependent CRISPR systems respond appropriately to dynamic disease st | resolved | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Do off-target epigenetic modifications from CRISPR-based epigenome editing cause | open | 0.85 | 0.00 | 2026-04-10 | 0 | | safety-pharmacology |
| gap-debate-20260410- | What delivery mechanisms can achieve therapeutically relevant CRISPR concentrati | partially_addressed | 0.95 | 0.00 | 2026-04-10 | 0 | | drug-delivery |
| gap-debate-20260410- | How can CRISPR systems achieve persistent therapeutic effects while avoiding chr | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | gene-therapy |
| gap-debate-20260410- | What are validated biomarkers for measuring senescent cell clearance and target | open | 0.75 | 0.00 | 2026-04-10 | 0 | | translational-medicine |
| gap-debate-20260410- | Do senescent neurons become 'super-spreaders' of pathological tau through enhanc | open | 0.80 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | Which specific SASP components drive neurodegeneration versus neuroprotection in | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-debate-20260410- | Can P16INK4A expression reliably distinguish harmful from beneficial senescent m | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How do proposed therapeutic mechanisms avoid off-target effects across multiple | open | 0.71 | 0.00 | 2026-04-10 | 0 | | pharmacology |
| gap-debate-20260410- | What are the cell-type-specific transcriptomic signatures of vulnerability in SE | partially_addressed | 0.88 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Does ST6GALNAC5 silencing in astrocytes translate from rodent models to human AD | open | 0.75 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | What is the validity of TREM2-APOE4 protein-protein interactions as therapeutic | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Can selective modulation of 14-3-3 protein isoforms differentially affect tau pr | open | 0.71 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Which specific HSP90 co-chaperone interactions promote versus prevent tau pathog | open | 0.75 | 0.00 | 2026-04-10 | 0 | | protein-biochemistry |
| gap-debate-20260410- | What are the optimal temporal dynamics for GSK3β inhibition to block pathologica | open | 0.78 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | Does FYN kinase directly regulate tau packaging into extracellular vesicles or o | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What manufacturing processes can produce therapeutic synthetic EVs at clinical s | open | 0.75 | 0.00 | 2026-04-10 | 0 | | biotechnology |
| gap-debate-20260410- | What is the relative contribution of EV-mediated versus direct cell-to-cell tau | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How do synthetic EVs achieve brain-specific targeting while avoiding reticuloend | partially_addressed | 0.88 | 0.00 | 2026-04-10 | 0 | | drug-delivery |
| gap-debate-20260410- | What are the competitive binding kinetics between synthetic EV decoys and endoge | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How do circadian epigenetic cycles causally contribute to neuronal aging versus | open | 0.79 | 0.00 | 2026-04-10 | 0 | | chronobiology |
| gap-debate-20260410- | What is the optimal temporal pattern for oscillating epigenetic enzyme activity | open | 0.75 | 0.00 | 2026-04-10 | 0 | | chronobiology |
| gap-debate-20260410- | Are age-related static epigenetic patterns pathogenic or protective compensatory | partially_addressed | 0.88 | 0.00 | 2026-04-10 | 0 | | epigenetics |
| gap-debate-20260410- | Can TET2 enzymatic activity be selectively modulated in neurons without systemic | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Can PINK1/Parkin mitophagy pathway restoration rescue SIRT3-mediated mitochondri | open | 0.79 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | How do circuit-level connectivity patterns versus cell-intrinsic metabolism dete | resolved | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What determines the GPX4/ACSL4 balance that switches microglia from protective t | partially_addressed | 0.88 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | Does SIRT3 downregulation cause or result from mitochondrial dysfunction in vuln | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How does TFEB-PGC1α decoupling create selective neuronal vulnerability to protei | open | 0.79 | 0.00 | 2026-04-10 | 0 | | cellular-biology |
| gap-debate-20260410- | Which specific cell types drive complement system activation in the aging brain? | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroimmunology |
| gap-debate-20260410- | What is the temporal sequence of TREM2 signaling transition from protective to i | partially_addressed | 0.88 | 0.00 | 2026-04-10 | 0 | | neuroimmunology |
| gap-debate-20260410- | Does SPARC upregulation in aging represent pathogenic synaptic pruning or failed | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Which astrocyte subpopulations drive neuroinflammation versus neuroprotection in | open | 0.71 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What are the long-term safety implications of chronic PARP1 modulation in the ag | open | 0.75 | 0.00 | 2026-04-10 | 0 | | pharmacology |
| gap-debate-20260410- | How can TREM2 agonists be delivered specifically to disease-associated microglia | open | 0.78 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | Is oligodendrocyte DNA damage a primary driver or secondary consequence of AD pa | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What temporal sequence governs cell-type vulnerability progression in early-stag | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How do SYK inhibition effects differ between neuroprotective and neurotoxic micr | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-debate-20260410- | What are the cell-type specific mechanisms of TIM-3 regulation in AD microglia v | open | 0.78 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | Is oligodendrocyte DNA damage a primary driver or secondary consequence of AD pa | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How do cell-type-specific vulnerabilities temporally sequence during AD pathogen | resolved | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Can TREM2 be safely enhanced without promoting harmful microglial activation sta | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | What determines layer-specific vulnerability of CUX2/RORB excitatory neurons in | open | 0.85 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | Do oligodendrocytes require DNA repair enhancement or inhibition for neuroprotec | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Why do microglial enhancement strategies show non-linear dose-response relations | open | 0.75 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | Can therapeutic interventions achieve cell-type selectivity without disrupting e | open | 0.80 | 0.00 | 2026-04-10 | 0 | | drug-development |
| gap-debate-20260410- | What determines cell-type-specific vulnerability patterns beyond transcriptomic | open | 0.85 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | Do tau aggregates represent protective responses or primary pathogenic drivers i | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Can lysosomal membrane stabilizers selectively prevent tau seeding without disru | open | 0.70 | 0.00 | 2026-04-10 | 0 | | cell-biology |
| gap-debate-20260410- | How do species differences in P2RX7 function between rodents and humans affect t | open | 0.80 | 0.00 | 2026-04-10 | 0 | | translational-medicine |